<DOC>
	<DOC>NCT01147289</DOC>
	<brief_summary>A phase III, randomized, multicenter, open label clinical trial to evaluate efficacy and safety of the injectable association of dexamethasone, dipyrone, and hydroxocobalamin in lumbar sciatic pain. The study will enroll 140 patients in each arm (280 total).</brief_summary>
	<brief_title>Efficacy and Safety of Injectable Association of Dexamethasone, Dipyrone and Hydrocobalamin in Lumbar Sciatic Pain</brief_title>
	<detailed_description />
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dipyrone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<criteria>Sign the study informed consent form; To be diagnosed with moderate to severe lumbar sciatic pain (defined as limiting the work activities or the ordinary tasks performance or at the investigator's discretion) within the last 3 days; Aged 18 to 75 years old; To be able to meet the study procedures oDiagnosed with chronic rheumatologic diseases, except recurrent lumbar sciatic pain; Patients with one of the following conditions, as per the investigator's criteria: Severe renal failure under hemodialysis, severe liver failure, uncontrolled severe heart failure; Severe injuries on gastrointestinal tract; Other severe comorbidities; Patients taking acetylsalicylic acid or any anticlotting; Female patients who are pregnant, lactating, willing to get pregnant or not willing to use an appropriate contraceptive method during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>lumbar sciatic pain</keyword>
	<keyword>moderate to severe lumbar sciatic pain within the last three days</keyword>
</DOC>